Compare New York Times Co (NYT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Recursion Pharmaceuticals Inc — how do they compare? New York Times Co trades at $66.6 (market cap $10.96B), while Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B). The key difference: New York Times Co is far larger — about 5.9× Recursion Pharmaceuticals Inc's market cap, and New York Times Co pays a 1.35% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NYT | RXRX | |
|---|---|---|
Market Cap | $10.96B | $1.86B |
Sector | Media | Health |
52-Week High | $85.86 | $6.79 |
52-Week Low | $54.66 | $2.84 |
Enterprise Value | $10.36B | $1.38B |
Dividend Yield | 1.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $67.96, up 1.01% today, with a neutral technical signal and mixed moving averages. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $0.69 exceeding the $0.663 forecast. Revenue growth is steady, rising from $2.3B in 2022 to $2.8B in 2025, with net profit margins improving to 12.17%. The company maintains strong cash flow from operations at $584.49M in 2025. Analyst consensus is a $76.00 price target, though the majority recommend Hold.
Outlook remains cautiously optimistic given earnings momentum and solid fundamentals, but risks include the ongoing OpenAI copyright lawsuit and competitive pressures in digital media. The stock offers potential upside to the consensus target, supported by institutional buying interest, though sentiment is tempered by regulatory and litigation uncertainties.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
